Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Shares of SpringWorks Therapeutics (NASDAQ:SWTX) reached a session high on Thursday after The Wall Street Journal reported ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...

Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Recent health news highlights financial and strategic developments in major pharmaceutical companies like Gilead and Merck, ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

BofA is moving to No Rating on SpringWorks Therapeutics (SWTX) given that shares are trading near the Merck KGaA (MKGAY) potential offer price ...

Gilead Sciences reports profits but mixed revenue; Merck is in talks to acquire SpringWorks for $3.5 billion; measles cases ...

SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The ...